Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Roisin M. Connolly, MD, on Breast Cancer Treatment Advances in 2018 and NCCN Clinical Practice Guidelines

Posted: Friday, December 21, 2018

Roisin M. Connolly, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses clinical trials during the past year on studies on CDK and PI3K inhibitors in estrogen receptor–positive breast cancer and immune checkpoint agents in triple-negative breast cancer and their bearing on the NCCN Guidelines.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.